MMJ Recs

MAY 9, 2024

In this instance, medical cannabis offers a promising alternative or complementary treatment option. As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

FEBRUARY 9, 2023

Although many rely on imaging scans to diagnose illnesses and get treatment of various kinds, getting into the enclosed chamber can be stressful. A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures.

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. Availability of other information about COMPASS Pathways.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. Over the prior three years or so, 41,260 RYAH-connected patients reported medical cannabis use for the treatment of pain.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

OCTOBER 22, 2021

Medicines and Healthcare products Regulatory Agency (the “ MHRA ”), Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate from its pipeline of N,N-dimethyltryptamine (“ DMT ”) assisted therapies for the treatment of major depressive disorder (“ MDD ”). About Small Pharma.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

APRIL 2, 2022

a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil (the “Ibogaine Group”). Upon signing a definitive agreement, Bienstar will have access to a broad patient base in Brazil-the largest market in Latin America with 215 million people.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Project CBD

NOVEMBER 11, 2023

And then cannabis has unique effects for a wide range of conditions, everything from the treatment of pain, treatment of asthma, treatment of immune conditions. Dr. Weil: Yes, first of all, there’s been a big demand for information about cannabis from our Fellows, the people in our programs, they want to learn about it.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes. of prescriptions were for sleep disorders. Read their full article at.

Medicine 52

Medicine Clinical Trials Data Sleep 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Patients can also access CBD products without a prescription through local pharmacies. Parkinson’s disease and cannabis.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

MAY 3, 2022

a necessary question to address as medical marijuana becomes more accessible. Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. Daily Cannabis Use as a Disqualifier.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Veriheal

MAY 26, 2022

RoC also works to increase patients’ access to medical cannabis by helping U.S. Much like RoC, patient advocacy is at the forefront of Veriheal’s work, which includes connecting patients with medical marijuana (MMJ) doctors, collecting patient data to improve future treatment, and battling harmful cannabis stigmas with education.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

DECEMBER 9, 2021

Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. MIAMI , Dec. ” About Nue Life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The goal at TrPR is to accelerate progress towards impactful and accessible psychedelic treatments.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

MMJ Recs

JUNE 15, 2022

There are many treatments that can be utilized along with MMJ products to alleviate pain, such as medications, physical therapy, and massage. The best pain management physicians collaborate with the patient to develop a treatment regimen that works best for them as an individual. Pain Treatment Specialists.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Veriheal

SEPTEMBER 6, 2022

In a systematic review published in 2017 , researchers found that “Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Clinical trials and placebo-controlled studies are needed to confirm the findings found in this review.

Sleep 105

Sleep THC CBD Chronic Pain 105

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

JANUARY 12, 2022

This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. MAPS PBC is pioneering new forms of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for post-traumatic stress disorder (PTSD). About MAPS Public Benefit Corporation (MAPS PBC). Executive Summary.

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. This prompted some states to take the first steps toward legalizing medical marijuana.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Veriheal

JULY 12, 2021

Fortunately, congressional committees are fighting for medical cannabis access for veterans , and states are beginning to take measures to address their veterans , but what is the latest in research and what can one expect? At this time, there is little in the way for combat-related PTSD treatment specifically. Let’s find out. .

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. n) any related matters.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

Peninsula Alternative Health

MAY 15, 2019

With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Cannabis Law Report

JUNE 3, 2022

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59